sinc
decemb
novel
coronaviru
pneumonia
ncp
case
emerg
wuhan
china
novel
coronaviru
confirm
caus
ncp
number
infect
patient
china
increas
rapidli
exceed
previou
report
clinic
characterist
ncp
patient
investig
report
mortal
respect
organ
dysfunct
coagulopathi
associ
high
mortal
howev
complet
coagul
paramet
ncp
case
fulli
report
may
prognost
valu
import
therapeut
target
studi
coagul
paramet
consecut
ncp
case
hospit
shown
differ
survivor
investig
consecut
patient
confirm
ncp
admit
tongji
hospit
huazhong
univers
scienc
technolog
wuhan
januari
februari
enrol
studi
approv
ethic
committe
tongji
hospit
wuhan
china
diagnosi
ncp
accord
world
health
organ
interim
guidanc
confirm
rna
detect
clinic
laboratori
tongji
hospit
clinic
outcom
monitor
februari
sampl
coagul
test
collect
admiss
hospit
stay
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
antithrombin
activ
fibrinogen
fibrin
degrad
product
fdp
detect
use
max
coagul
analyz
origin
reagent
diagnostica
stago
franc
survivor
normal
abnorm
distribut
quantit
variabl
compar
use
student
test
u
test
respect
categor
variabl
compar
use
test
result
given
mean
standard
deviat
median
interquartil
rang
number
percentag
wherev
appropri
consid
statist
signific
data
analyz
use
spss
window
spss
inc
patient
femal
male
ncp
enrol
studi
patient
complet
clinic
inform
laboratori
data
requir
studi
mean
age
diseas
onset
year
rang
year
patient
chronic
diseas
includ
cardiovascular
cerebrovascular
diseas
respiratori
system
diseas
malign
tumor
chronic
liver
kidney
diseas
other
patient
receiv
antivir
support
therapi
diagnosi
end
februari
patient
discharg
patient
die
rest
patient
remain
hospit
stabl
condit
coagul
paramet
admiss
survivor
compar
tabl
base
detect
system
report
rang
fdp
respect
dynam
chang
coagul
paramet
track
day
day
admiss
interv
figur
accord
intern
societi
thrombosi
haemostasi
isth
diagnost
criteria
dissemin
intravascular
coagul
dic
match
grade
point
later
stage
ncp
tabl
median
time
admiss
dic
day
rang
day
contrari
one
survivor
match
dic
criteria
hospit
stay
enrol
patient
ncp
reveal
significantli
higher
fdp
level
longer
pt
compar
survivor
admiss
late
hospit
fibrinogen
level
also
significantli
lower
suggest
convent
coagul
paramet
cours
ncp
significantli
associ
prognosi
dic
appear
death
patient
present
viru
infect
may
develop
sepsi
associ
organ
dysfunct
sepsi
well
establish
one
common
caus
dic
develop
dic
result
monocyt
endotheli
cell
activ
point
cytokin
releas
follow
injuri
express
tissu
factor
secret
von
willebrand
factor
circul
free
thrombin
uncontrol
natur
anticoagul
activ
platelet
stimul
fibrinolysi
late
stage
ncp
level
marker
fdp
moder
markedli
elev
death
suggest
common
coagul
activ
secondari
hyperfibrinolysi
condit
patient
previou
studi
gralinski
et
al
investig
viral
pathogenesi
identifi
novel
host
pathway
involv
sever
acut
respiratori
syndrom
sar
diseas
progress
data
suggest
dysregul
urokinas
pathway
infect
contribut
sever
lung
patholog
plasminogen
activ
play
protect
role
follow
infect
addit
fatma
berri
et
al
report
plasminogen
contribut
inflamm
caus
influenza
fibrinolysi
acid
protect
influenza
presum
fibrinolysi
may
also
induc
follow
sever
infect
limit
report
includ
rel
small
studi
mortal
characterist
enrol
patient
may
repres
find
confirm
adequ
power
clinic
studi
addit
patient
still
hospit
time
manuscript
submiss
nonetheless
present
studi
shown
exist
dic
common
death
ncp
abnorm
coagul
result
especi
markedli
elev
fdp
may
potenti
guid
therapi
evalu
prognosi
n
tang
x
wang
collect
clinic
data
process
statist
data
n
tang
li
draft
revis
manuscript
z
sun
design
guid
studi
author
declar
conflict
interest
